Filing Details

Accession Number:
0000950170-24-043502
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-10 20:50:27
Reporting Period:
2024-04-08
Accepted Time:
2024-04-10 20:50:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1157601 Madrigal Pharmaceuticals Inc. MDGL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1236927 A Paul Friedman C/O Madrigal Pharmaceuticals, Inc.
200 Barr Harbor Drive, Suite 400
West Conshohocken PA 19428
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-04-08 26,270 $9.45 212,005 No 4 M Direct
Common Stock Disposition 2024-04-08 1,441 $242.95 210,564 No 4 S Direct
Common Stock Disposition 2024-04-08 3,730 $244.12 206,834 No 4 S Direct
Common Stock Disposition 2024-04-08 5,663 $244.86 201,171 No 4 S Direct
Common Stock Disposition 2024-04-08 2,078 $245.71 199,093 No 4 S Direct
Common Stock Disposition 2024-04-08 5,028 $246.96 194,065 No 4 S Direct
Common Stock Disposition 2024-04-08 3,464 $247.76 190,601 No 4 S Direct
Common Stock Disposition 2024-04-08 4,866 $248.59 185,735 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-04-08 26,270 $0.00 26,270 $9.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
206,256 2026-07-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 655,540 Indirect By SQN LLC
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.39 to $243.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.43 to $244.42, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.43 to $245.42, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.43 to $246.28, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.45 to $247.43, inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.47 to $248.24, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.47 to $248.64, inclusive.
  9. The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  10. The shares underlying this stock option are fully vested and exercisable.